—I wish to thank Dr Wilkinson for his stated position vis-a-vis methylprednisolone acetate and its intraspinal therapy. His points are these: (1) the risks of its use are miniscule compared with clinical efficacy, (2) few patients have had complications following its intrathecal use, and (3) the neurochemistry of polyethylene glycol was inaccurately reported by myself.1Goldstein et al2 were the first to describe adhesive arachnoiditis from methylprednisolone acetate followed by 10 case reports by Nelson et al and Nelson,1 as well as Bernat et al and Bernat,3 who reported arachnoiditis and pachymeningitis. Two patients underwent an operation, and the pathologic findings in the lumbar region of one revealed a thin gelatinous material that I did not believe was disk material, but was a component of methylprednisolone acetate.4 During this same time period, numerous complications and infections were reported.5,6At first, the 20 case reports
Nelson DA. Dangers From Methylprednisolone Acetate Therapy by Intraspinal Injection-Reply. Arch Neurol. 1989;46(7):721–722. doi:10.1001/archneur.1989.00520430015008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: